Use of probiotics as a prospective biotherapy in the treatment of the metabolic syndrome

GAUFFIN CANO P.; RUSSO M.; MARQUEZ A.; ABEIJÓN-MUKDSI, CLAUDIA; MEDINA R.

Investigación en Salud

Ministerio de Salud Pública - Gobierno de Tucumán

Lugar: Tucumán Capital; Año: 2018 vol. 2 p. 24 - 26

2591-3026

Probiotics are live microorganisms which when administered in adequate concentrations confer a benefit on the health of the host. Currently,a second generation probiotics emerged, which are aimed at preventing or improving specific changes in the gut microbiota and thus interacting with the host to improve the metabolic-immune alterations related to the metabolic syndrome (MS).In this context, in vitro, ex vivo and preclinicals studies were carried out with Lactobacillus (L.) fermentum CRL1446. The continuous oral administration of L. fermentum CRL1446 in different murine model of MS induce significant modifications of metabolic parameters and the intestinal microbiota (reduction in the Firmicutes/Bacteroidetes ratio). The observed metabolic changes werw a decrease in body weight, the adiposity index and improvements in the lipid profile (triglycerides,total cholesterol and HDL-cholesterol) glycemia, glucose tolerance, insuline and plasma leptin.The in vitro, ex vivo and preclinical studies show that the probiotic strain, L. fermentum CRL1446, could be used in the treatmen and/or prevention of metabolic syndrome and phatologies associated with malnutrition. This strain achieves this beneficial efects by modulation of intestinal microbiota and by its properties such as inhibitory capacity of alfa-glucosidase activity, assimilation of cholesterol, etc.